Sonoma Pharmaceuticals (SNOA) said late Monday the US Food and Drug Administration has granted a new 510(k) clearance for its Microcyn technology-based hydrogel for wound treatment.
The clearance allows the product to be used, under the supervision of a healthcare professional, for wounds associated with dermal irritation, sores, injuries and ulcers of dermal tissue, first and second degree burns, diabetic ulcers, and mechanically or surgically-debrided wounds, the company said.
The clearance applies to 50 milliliter bottles with a shelf life of 24 months, it said.
Price: 2.9600, Change: -0.14, Percent Change: -4.52
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。